Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Stock Exchange of Hong Kong  >  Beigene Ltd       

BEIGENE LTD

SummaryNewsRatingsCalendarCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. (NASDAQ: BGNE) on Behalf of BeiGene Stockholders and Encourages BeiGene Investors to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/13/2019 | 10:01pm EDT

Bragar Eagel & Squire, P.C. is investigating potential claims against BeiGene, Ltd. (NASDAQ: BGNE) on behalf of BeiGene stockholders. Our investigation concerns whether BeiGene has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On September 5, 2019, J Capital Research (“J Capital”) published a report on BeiGene. The J Capital report asserted that BeiGene “is faking sales in order to persuade investors that it can develop a successful platform in China” and that “management may also be skimming R&D and capital budgets.”

On this news, BeiGene’s American depositary share price fell $19.95 per share, or 14.19%, to close at $120.61 per share on September 6, 2019.

If you purchased or otherwise acquired BeiGene shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into BeiGene please go to http://www.bespc.com/BGNE. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BEIGENE LTD
09/23BGNE LOSS NOTICE : ROSEN, A LEADING LAW FIRM, Continues to Investigate Securitie..
BU
09/16GLANCY PRONGAY & MURRAY LLP : Continues Its Investigation on Behalf of BeiGene, ..
BU
09/16Law Offices of Howard G. Smith Continues Its Investigation on Behalf of BeiGe..
BU
09/13BRAGAR EAGEL & SQUIRE, P.C. IS INVES : BGNE) on Behalf of BeiGene Stockholders a..
BU
09/13GLANCY PRONGAY & MURRAY LLP : Announces Investigation on Behalf of BeiGene, Ltd...
BU
09/12Law Offices of Howard G. Smith Announces Investigation on Behalf of BeiGene, ..
BU
09/12INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claim..
BU
09/12Investigation of BeiGene Announced by Holzer & Holzer, LLC
BU
09/12BEIGENE : Announces Clinical Data to Be Presented at the Annual Meeting of the C..
AQ
09/11INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims A..
BU
More news
Managers
NameTitle
John V. Oyler Chairman & Chief Executive Officer
Xiao Dong Wang Director
Maggie Liu Head-Operations
Howard Liang Chief Financial & Strategy Officer
Jane E Huang Chief Medical Officer-Hematology
Sector and Competitors
1st jan.Capitalization (M$)
BEIGENE LTD8 181
GILEAD SCIENCES5.08%83 244
VERTEX PHARMACEUTICALS6.14%45 207
REGENERON PHARMACEUTICALS-21.10%32 247
GENMAB31.62%13 446
NEUROCRINE BIOSCIENCES, INC.40.15%9 165